Peter Mugyenyi | Academic Influence

Peter Mugyenyi's AcademicInfluence.com Rankings

Peter Mugyenyi

Philosophy

#11807

World Rank

#16318

Historical Rank

Logic

#8617

World Rank

#10803

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Peter Mugyenyi's Degrees

Doctorate Medicine Makerere University

Why Is Peter Mugyenyi Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Peter Ndimbirwe Mugyenyi, MBChB, DCH, FRCPI, FRCPE, ScD is a Ugandan physician, HIV/AIDS researcher, medical administrator and author. He is executive director and co-founder of the Joint Clinical Research Centre, and a leading authority on treatment of HIV/AIDS in Africa.

(See a Problem?)

Peter Mugyenyi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. (2011) (557)
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. (1997) (423)
Depletion of Regulatory T Cells in HIV Infection Is Associated with Immune Activation1 (2005) (394)
Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance (2002) (354)
Multiple Validated Measures of Adherence Indicate High Levels of Adherence to Generic HIV Antiretroviral Therapy in a Resource-Limited Setting (2004) (307)
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda (2007) (283)
Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy (2005) (253)
Impact of tuberculosis (TB) on HIV‐1 activity in dually infected patients (2001) (184)
Assessment of second-line antiretroviral regimens for HIV therapy in Africa. (2014) (183)
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections (2004) (182)
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults (2001) (166)
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. (2008) (159)
Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort (2010) (140)
Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. (1999) (138)
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda (2007) (136)
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa (2017) (136)
Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa (2006) (130)
Hematological reference ranges among healthy Ugandans (1995) (120)
Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. (2001) (117)
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. (2005) (109)
Increased Replication of HIV‐1 at Sites of Mycobacterium tuberculosis Infection: Potential Mechanisms of Viral Activation (2001) (106)
Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults with HIV Infection within the Dart Trial (2005) (104)
Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial (2013) (98)
T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. (2005) (98)
Scale-up of HIV Treatment Through PEPFAR: A Historic Public Health Achievement (2012) (92)
A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. (1995) (90)
T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB) (2000) (85)
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. (2016) (81)
Highly active antiretroviral therapy (2004) (78)
Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa (2013) (77)
Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe (2012) (75)
Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. (2000) (75)
High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. (2004) (72)
Discontinuation and Modification of Highly Active Antiretroviral Therapy in HIV-Infected Ugandans: Prevalence and Associated Factors (2007) (69)
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. (2003) (69)
Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa (2016) (66)
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. (2010) (64)
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial (2016) (63)
Factors Associated with Intention to Conceive and its Communication to Providers Among HIV Clients in Uganda (2012) (59)
Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. (2016) (57)
Expanding HIV care in Africa: making men matter (2009) (57)
Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study (2012) (54)
First trial of the HIV-1 vaccine in Africa: Ugandan experience (2002) (52)
Antiretroviral treatment in resource-poor settings: clinical research priorities (2002) (52)
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults (2014) (51)
Diminishing Availability of Publicly Funded Slots for Antiretroviral Initiation among HIV-Infected ART-Eligible Patients in Uganda (2010) (50)
Understanding the influence of depression on self-efficacy, work status and condom use among HIV clients in Uganda. (2011) (50)
Coinfection with Schistosoma mansoni Is Associated with Decreased HIV-Specific Cytolysis and Increased IL-10 Production1 (2005) (49)
HIV-Specific IL-10-Positive CD8+ T Cells Are Increased in Advanced Disease and Are Associated with Decreased HIV-Specific Cytolysis1 (2006) (47)
Lymphoid tissue fibrosis is associated with impaired vaccine responses (2018) (46)
Global threat from drug resistant HIV in sub-Saharan Africa (2012) (46)
Impact of HIV Antiretroviral Therapy on Depression and Mental Health Among Clients With HIV in Uganda (2012) (45)
High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy (2013) (44)
HIV-1 risk and vaccine acceptability in the Ugandan military. (1997) (43)
The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children (2010) (43)
Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. (2013) (42)
Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure (2016) (40)
Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy (2016) (39)
Factors Associated with Condom Use Among HIV Clients in Stable Relationships with Partners at Varying Risk for HIV in Uganda (2010) (38)
Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration. (1998) (36)
Mechanisms of Apoptosis of T-Cells in Human Tuberculosis (2005) (36)
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda (2009) (35)
Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe (2012) (35)
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial (2012) (35)
A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to Continuous Antiretroviral Therapy for the Treatment of HIV Infection in Uganda (2010) (35)
Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children (2017) (34)
Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. (2006) (34)
Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period (2013) (34)
Characterization of a Subtype D Human Immunodeficiency Virus Type 1 Isolate That Was Obtained from an Untreated Individual and That Is Highly Resistant to Nonnucleoside Reverse Transcriptase Inhibitors (2004) (33)
HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda (2016) (33)
Resistance to antiretroviral therapy among patients in Uganda. (2001) (32)
Validation of World Health Organisation HIV/AIDS Clinical Staging in Predicting Initiation of Antiretroviral Therapy and Clinical Predictors of Low CD4 Cell Count in Uganda (2011) (31)
A qualitative analysis of the economic impact of HIV and antiretroviral therapy on individuals and households in Uganda. (2009) (31)
Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults. (2003) (30)
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial (2018) (30)
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy (2007) (30)
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial (2010) (30)
The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda (2009) (30)
Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. (2008) (30)
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48‐week randomized comparison with abacavir/zidovudine/lamivudine in HIV‐infected Ugandan adults with low CD4 cell counts (2010) (28)
Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. (2008) (27)
HIV vaccines: the Uganda experience. (2002) (27)
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial (2018) (27)
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial (2018) (27)
Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. (2009) (26)
Depression in the Pathway of HIV Antiretroviral Effects on Sexual Risk Behavior Among Patients in Uganda (2012) (26)
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa (2017) (25)
Towards 90-90-90 Target: Factors Influencing Availability, Access, and Utilization of HIV Services—A Qualitative Study in 19 Ugandan Districts (2018) (25)
Human Immunodeficiency Virus-Specific Responses in Adult Ugandans: Patterns of Cross-Clade Recognition (2005) (25)
Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial. (2019) (24)
Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial (2018) (24)
Diversity of the vif gene of human immunodeficiency virus type 1 in Uganda. (1997) (24)
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. (2019) (22)
Role of antiretroviral therapy in improving food security among patients initiating HIV treatment and care (2012) (22)
A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria (2013) (22)
Prevalence of Lipodystrophy and Metabolic Abnormalities in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy (2015) (22)
Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART (2013) (21)
Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. (2018) (20)
Translocated microbiome composition determines immunological outcome in treated HIV infection (2021) (20)
Low Incidence of Abacavir Hypersensitivity Reaction Among African Children Initiating Antiretroviral Therapy (2011) (20)
A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL. (2011) (20)
Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy. (2013) (20)
Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection (2018) (19)
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. (2008) (19)
Widow inheritance and HIV/AIDS in rural Uganda (2007) (19)
Cost Effectiveness Analysis of Routine Laboratory or Clinically Driven Strategies for Monitoring Anti-Retroviral Therapy in Uganda and Zimbabwe (DART Trial) (2009) (18)
ORPHANHOOD PREDICTS DELAYED ACCESS TO CARE IN UGANDAN CHILDREN (2009) (17)
The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models (2015) (17)
Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda (2016) (16)
Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda. (2012) (16)
HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. (2014) (16)
Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial (2016) (14)
Antiretroviral treatment in Africa. (1997) (14)
Impact of routine laboratory monitoring over 5 years after antiretroviral therapy (ART)initiation on clinical disease progression of HIV-infected African adults: the DART Trial finalresults (2009) (13)
Genocide by Denial: How Profiteering from HIV/AIDS Killed Millions (2008) (13)
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. (2008) (12)
Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance (2016) (12)
A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child. (2011) (11)
Presence of distinct subsets of cytolytic CD8+ T cells in chronic HIV infection. (2006) (11)
Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries (2017) (10)
High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial (2014) (9)
Flat-line funding for PEPFAR: a recipe for chaos (2009) (9)
Sexual behaviour among persons living with HIV/AIDS in Kampala, Uganda. (2010) (9)
Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. (1997) (9)
Clinical Differences between Younger and Older Adults with HIV/AIDS Starting Antiretroviral Therapy in Uganda and Zimbabwe: A Secondary Analysis of the DART Trial (2013) (9)
Expression of chemokine receptors on CD4+ T cells in peripheral blood from HIV-infected individuals in Uganda. (2000) (8)
When prevention of mother-to-child HIV transmission fails: preventing pretreatment drug resistance in African children. (2017) (8)
Pharmacokinetics of Zidovudine Dosed Twice Daily According to World Health Organization Weight Bands in Ugandan HIV-infected Children (2014) (8)
CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria. (2006) (8)
Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study. (2011) (8)
Psychosocial Characterization of HIV Clients With Potential To Be Change Agents For HIV Prevention in Uganda (2012) (7)
O087 Leveraging existing HIV/AIDS infrastructure for rheumatic heart disease care in Uganda: a collaborative disease surveillance and management program (2014) (7)
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial (2018) (7)
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial (2018) (7)
Lessons From Africa (2010) (6)
Opportunities for improving the efficiency of paediatric HIV treatment programmes (2015) (6)
Effectiveness of a mobile antiretroviral pharmacy and HIV care intervention on the continuum of HIV care in rural Uganda (2019) (5)
Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children. (2019) (5)
Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost (2015) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa. (2012) (5)
Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis (2016) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Need for review of prevention of mother-to-child transmission practice especially in discordant couples: a case of mother-to-child transmission of HIV during breast feeding by a mother who tested HIV negative antenatally. (2007) (4)
Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings. (2019) (4)
Sustainable and cost-effective monitoring of patients on ART. (2014) (4)
A qualitative exploration of the impact of HIV and ART on social disruption and household continuity in Uganda (2011) (4)
O086 Does HIV infection modify the risk of RHD? Initial echocardiographic screening experience at the Joint Clinical Research Centre in Kampala, Uganda (2014) (3)
Superior virological suppression with nevirapine/zidovudine/lamivudine versus abacavir/zidovudine/lamivudine without evidence of clinical benefit to 48 weeks: a randomised comparison in patients with low CD4 counts in Africa. (2007) (3)
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda (2014) (3)
Second-line treatment in sub-Saharan Africa: week 144 follow-up of the EARNEST trial (2015) (2)
Discordance between virological/immunological and clinical outcomes at 48 weeks, in a randomised comparison of ZDV/3TC/NVP and ZDV/3TC/ABC in patients with low CD4 counts in Africa. (2007) (2)
Persistence of traditional and emergence of new structural drivers and factors for the HIV epidemic in rural Uganda; A qualitative study (2019) (2)
Empiric Tuberculosis Therapy versus Isoniazid in Advanced HIV-infected Adult Outpatients Initiating Antiretroviral Therapy : a Multi-Country Randomized Controlled Trial (2016) (2)
Scaling up antiretroviral therapy : experience of the Joint Clinical Research Centre (JCRC) access programme (2006) (2)
Pharmacokinetics of Once versus Twice Daily Lamivudine and Abacavir in HIV-1 Infected Ugandan Children in the ARROW trial. (2009) (1)
The Development of Anti-Retroviral Therapy in Africa (DART) trial. Comparison of routine vs clinically driven laboratory monitoring in HIV-infected African adults over 5 years on ART: Final results of the DART trial. (2009) (1)
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults (2014) (1)
ARROW study design and baseline characteristics: AntiRetroviral Research fOr Watoto. (2008) (1)
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min (2019) (1)
Long-term randomised comparison of clinical outcomes following ART initiation with triple-nucleoside (Combivir/Abacavir) or NNRTI-based (Combivir/Nevirapine) therapy in Africa: the NORA substudy of the DART trial. (2009) (1)
Strengthening Institutional Research Administration in Uganda: A Case Study on Developing Collaborations among Academic and Research Institutions (2012) (1)
Determinants of Clinician Knowledge on Aging and HIV/AIDS: A Survey of Practitioners and Policy Makers in Kampala District, Uganda (2013) (1)
Plasma levels of nevirapine following interruption of ZDV/3TC/NVP in African adults within the DART trial. (2006) (1)
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial (2022) (1)
Differences in Resistance Mutations in Non-B Subtypes at First-line Failure in Africa (2015) (1)
Successful management of suspected Abacavir hypersensitivity reactions among African children in the ARROW (AntiRetroviral Research for Watoto) trial (2009) (1)
Cytolysis and Increased IL-10 Production Associated with Decreased HIV-Specific Is Schistosoma mansoni Coinfection with Huyen (2005) (1)
Immune restoration over 5 years on ART among patients initiating treatment with advanced immune deficiency in the DART trial in Uganda and Zimbabwe. (2010) (1)
Supporting Information S1 (2010) (0)
Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda (2016) (0)
A pilot study of antituberculous combinations comparing rifabutin with rifampicin in Ugandan patients with HIV-1 infection and pulmonary tuberculosis (1994) (0)
Most cost-effective method to monitor ART in adults in Africa? (2014) (0)
P136 The clinical pattern, prevalence and factors associated with immune reconstitution inflammatory syndrome in children on HAART attending Joint Clinical Research Center (2009) (0)
Confidentiality and non-disclosure can affect enrolment, follow-up and adherence to Antiretroviral Therapy in Ugandan children. Findings from the ARROW (AntiRetroviral Research fOr Watoto) trial. (2008) (0)
Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa (2017) (0)
Treatment of HIV/AIDS with antiretroviral drugs (1999) (0)
Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe (2010) (0)
Research on traditional medicine for HIV treatment at the Joint Clinical Research Centre (JCRC) Kampala, Uganda (1997) (0)
HIV drug resistance among adults and children in sub-Saharan Africa (2013) (0)
Ready-to-Use Supplementary Food to Prevent Mortality in Severely Immunocompromised Individuals Initiating Antiretroviral Therapy in Africa: An Open-label Randomised Controlled Trial (2018) (0)
Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities (2005) (0)
Causes and timing of mortality and morbidity among late presenters starting ART in the REALITY trial (2018) (0)
OC 8450 ABSENCE OF MINORITY HIV-1 DRUG-RESISTANT VARIANTS FOLLOWING MOTHER-TO-CHILD TRANSMISSION DOES NOT PREDICT VIROLOGIC SUCCESS OF FIRST-LINE ANTIRETROVIRAL THERAPY (2019) (0)
Ethical and practical constraints to the participation of HIV-infected orphaned children in a clinical trial in Zimbabwe. Experiences from the AntiRetroviral Research for Watoto (ARROW) Trial. (2008) (0)
ActivationInfection Is Associated with Immune Depletion of Regulatory T Cells in HIV (2005) (0)
Diverse Human Immunodeficiency Virus–1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings (2020) (0)
873 Psychoscoial Barriers to Adherence of Subsidised Art in Children & Adolescents, Kampala, Uganda (2010) (0)
Pharmacokinetics of Efavirenz dosed according to the WHO weight-bands in children in Uganda. (2010) (0)
Bacteriology of ear discharge in HIV-infected children on ART in the ARROW trial in Uganda and Zimbabwe (2011) (0)
DART and laboratory monitoring of HIV treatment – Authors' reply (2010) (0)
No Need for Apologies (2011) (0)
Persistent galactorrhea in a postmenopausal woman with herpes zoster and HIV-1 infection (2006) (0)
Impact of daily cotrimoxazole prophylaxis in severely immunosuppressed adults in Africa started on combination ART in the DART trial. (2009) (0)
New Management, Consistent Focus (2005) (0)
Antiretroviral Drug Resistance Mutations in HIV-1 Infected Ugandan Children Perinatally Exposed to Single Dose Nevirapine Following Virologic Failure to an NNRTI Based Regimen (2010) (0)

This paper list is powered by the following services:

Other Resources About Peter Mugyenyi

en.wikipedia.org

What Schools Are Affiliated With Peter Mugyenyi?

Peter Mugyenyi is affiliated with the following schools:

Makerere University